Lmcg Investments LLC Boosts Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Lmcg Investments LLC boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 63.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 74,370 shares of the specialty pharmaceutical company's stock after purchasing an additional 28,907 shares during the quarter. Lmcg Investments LLC owned approximately 0.12% of Jazz Pharmaceuticals worth $9,233,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. LSV Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 1.5% in the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock valued at $311,699,000 after acquiring an additional 37,108 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after acquiring an additional 320,724 shares during the last quarter. Capital World Investors increased its holdings in shares of Jazz Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock valued at $236,860,000 after acquiring an additional 104,195 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after acquiring an additional 315,608 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Jazz Pharmaceuticals by 4.8% in the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock valued at $195,506,000 after acquiring an additional 72,007 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $2.33 during mid-day trading on Friday, reaching $111.13. 726,472 shares of the company were exchanged, compared to its average volume of 836,816. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The firm's 50-day simple moving average is $108.09 and its two-hundred day simple moving average is $120.98. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $6.85 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 1.04 and a beta of 0.33.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same period in the previous year, the business posted $2.68 earnings per share. The firm's revenue was down .5% compared to the same quarter last year. Equities analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on JAZZ. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Barclays reiterated an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Morgan Stanley dropped their price objective on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 3rd. Finally, JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $184.00.

Insiders Place Their Bets

In other news, CMO Robert Iannone sold 2,403 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $138.41, for a total value of $332,599.23. Following the completion of the sale, the chief marketing officer now directly owns 79,621 shares of the company's stock, valued at $11,020,342.61. This trade represents a 2.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Seamus Mulligan purchased 100,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 9th. The stock was acquired at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the acquisition, the director now directly owns 100,000 shares in the company, valued at approximately $9,826,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 6,543 shares of company stock valued at $845,628. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.